Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07516899) titled 'Mass Balance Study of [14C] LPM3770164 in Healthy Participants' on April 1.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Luye Pharma Group Ltd.

Condition: Huntington Disease

Intervention: Drug: [14C] LPM3770164

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: April 30, 2026

Target Sample Size: 8

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07516899

Published by HT Digital Content Services with permissi...